1996年6月－1997年8月，任广州中医药大学校长助理、副教授。

1997年9月－2000年7月，任广州中医药大学副校长、教授。

2000年8月－2000年12月，任香港浸会大学中医药学院常务副院长、教授。

2001年1月－2007年3月，任香港浸会大学中医药学院院长、教授。

2007年4月－2009年8月，任香港浸会大学中医药学院院长、讲座教授。

2009年9月－2011年6月，任香港浸会大学中医药学院院长、讲座教授，香港浸会大学岑尧宽岑碧泉纪念癌症炎症研究中心主任。

2011年7月－2012年12月，任澳门科技大学副校长、讲座教授，中药质量研究国家重点实验室（澳门科技大学）主任。

2013年1月－2020年12月，任澳门科技大学校长、讲座教授，中药质量研究国家重点实验室（澳门科技大学）主任。

2021年1月， 任澳门科技大学荣誉校长、讲座教授。

刘良长期从事中医药诊疗风湿病的临床和研究⼯作。他带领的研究团队首次在国际上创建了类风湿关节炎等风湿病IgG硫酸化N-糖链分子诊断新方法，国际学术期刊Nature Reviews Rheumatology为此专门发表研究亮点新闻，认为该方法解决了血清抗体阴性风湿病难诊断的技术难题，新发现的血清标志物应用前景广阔。

刘良与湖南正清制药集团合作，成功研发全国首个中药缓释剂——正清风痛宁缓释片，在全国广泛应用于治疗类风湿关节炎等疾病，被纳⼊国家医保药物和基本药物目录，该药也是世界上首个能够通过抑制前列腺素E2的终极合成酶mPGES-1的药物，其作用机制不同于COX2抑制剂抗炎药，故无引起心血管副作用的风险。

刘良的研究团队还建立了世界上首个大鼠肠道基因集，为开展肠微⽣态研究建立了新方法，亦发现了免疫细胞IKK-beta激酶的药物结合新靶位Cystin-46，并建立了新的小鼠模式动物群，这为研发新靶标抗炎药提供了新的技术平台。

作为专家委员会主席，刘良主持制定了《世界卫生组织亚太区传统医学发展策略》（2010-2020）和《中医拔罐治疗临床规范》。

截至2019年11月，刘良在SCI英文学术期刊发表研究论文230余篇，累计影响因子逾1060，包括Science和Nature增刊、Nature Medicine、Annals of the Rheumatic Diseases、Nature Communications、Microbiome、Pharmacology & Therapeutics等国际期刊。

据2019年12月澳门科技大学官网显示，刘良主编或参与编写出版学术专著及教材18部，包括一套三册的中医英文专著《Essentials of Chinese Medicine》，由出版机构Springer出版发行；主编出版《中药临床安全与合理用药》专著。

根据广州中医药大学官网显示，刘良院士在SCI学术期刊发表论文逾300篇，出版专著/教材20部。

主要SCI期刊论文

1. Fan XX, Pan HD, Li Y, Guo RJ, Leung Elaine LH, Liu L*. Novel therapeutic strategy for cancerand autoimmune conditions: Modulating cell metabolism and redox capacity.Pharmacology and Therapeutics. June 2018.

2. Li RZ, Fan XX, Duan FG, Jiang ZB, Pan HD, Luo LX, Zhou YL, Li Y, YaoXJ, Leung EL*, Liu L*.Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumorgrowth via calcium-induced DR4 upregulation. Cell Death Dis. 2018 Jun 13:9(6):696.

3. Pan HD, Guo RJ , Zhu J, Wang Q, Ju YM, Xie Y, Zheng YF, Wang ZF, Li T, Liu ZQ,Lu LL, Li F,Tong B, Xiao L, Xu X, Li RZ, Yuan ZW, Yang HM, Wang J, Kristiansen K, Jia HJ* and Liu L*. Agene catalogue of the Sprague-Dawley rat gut metagenome. GigaScience, May, 2018.

4. Zhu GY, Yang J, Yao X, Yang X, Fu J, Liu X, Bai LP, Liu L, Jiang ZH. (±)-sativamides a and b,two pairs of racemic nor-lignanamide enantiomers from the fruits of cannabis sativa(hemp seed) [J]. The Journal of organic chemistry, 2018, 83 (4), pp 2376–2381.

5. Wang QQ, Xu JH, Li Y, Huang JM, Jiang ZB, Wang YW, Liu L, Leung EL, Yao XJ. Identificationof a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer bystructure-based virtual screening [J]. Frontiers in pharmacology, 2018, 9:173.

6. Wan HY, Chen JL, Zhu XZ, Liu L, Wang JF, Zhu XM. Titania-coated gold nano-bipyramids forblocking autophagy flux and sensitizing cancer cells to proteasome inhibitor-induceddeath [J]. Advanced Science, 2018, 5 (3):1700585.

7. Su XH, Li T, Liu ZQ, Huang QC, Liao KS, Ren RT, Lu LL, Qi XX, Wang MJ, Chen JY, Zhou H,Leung EL, Pan HD, Liu J, Wang H, Huang LF, Liu L*. Licochalcone activates keap1-nrf2signaling to suppress arthritis via phosphorylation of p62 at serine 349 [J]. Free RadicalBiology and Medicine, 2018, 115:471-483.

8. Liu XY, Yang KY, Wang MQ, Kwok JSL, Zeng X, Yang ZY, Xiao XJ, Lau CPY, Li Y, Huang ZM, BaJG, Yim AK, Quyang CY, Ngai SM, Chan TF, Leung EL, Liu L, Liu ZG, Tsui SK. High-qualityassembly of dermatophagoides pteronyssinus genome and transcriptome reveals a widerange of novel allergens [J]. Journal of Allergy and Clinical Immunology, 2018 Jan 2. pii:S0091-6749(17)33013-0.

9. Wu JJ, Guo ZZ, Zhu YF, Huang ZJ, Gong X, Li YH, Son WJ, Li XY, Lou YM, Zhu LJ, Lu LL, LiuZQ, Liu L*. A systematic review of pharmacokinetic studies on herbal drug fuzi:Implications for fuzi as personalized medicine [J]. Phytomedicine, 2018, Mar 1. doi:10.1016/j.phymed.2018.03.001

10. Chen TB, Zuo YH, Dong GT, Liu L*, Zhou H. An integrated strategy for rapid discovery andidentification of quality markers in guanxin kangtai preparation using uhplc-tof/ms andmultivariate statistical analysis [J]. Phytomedicine, 2018 Mar 6. doi:10.1016/j.phymed.2018.03.005.

11. Leung EL, Luo LX, Liu ZQ, Wong VK, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M,Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L*. Inhibition of krasdependentlung cancer cell growth by deltarasin: Blockage of autophagy increases itscytotoxicity [J]. Cell death & disease, 2018, 9 (2):216.

12. Fan XX, Leung EL, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu J, WeiCL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L*. Suppression of lipogenesisvia reactive oxygen species–ampk signaling for treating malignant and proliferativediseases [J]. Antioxidants & redox signaling, 2018, 28 (5):339-357.

13. Zhuo Y, Wu JL, Yan X, Guo MQ, Liu N, Zhou H, Liu L*, Li N*. Strategy for hepatotoxicityprediction induced by drug reactive metabolites using human liver microsome and online2d-nano-lc-ms analysis [J]. Analytical chemistry, 2017, 89 (24):13167-13175.

14. Zhu MZ, Li N, Wang YT, Liu N, Guo MQ, Sun BQ, Zhou H, Liu L*, Wu JL*. Acid/salt/phgradient improved resolution and sensitivity in proteomics study using 2d scx-rp lc–ms [J].Journal of proteome research, 2017, 16 (9):3470-3475.

15. Yu J, Kong L, Zhang A, Han Y, Liu Z, Sun H, Liu L, Wang X. High-throughput metabolomicsfor discovering potential metabolite biomarkers and metabolic mechanism from theappswe/ps1de9 transgenic model of alzheimer’s disease [J]. Journal of proteomeresearch, 2017, 16 (9):3219-3228.

16. Zhou H, Liu JX, Luo JF, Cheng CS, Leung EL, Li Y, Su XH, Liu ZQ, Chen TB, Duan FG, Dong Y,Zuo YH, Li C, Lio CK, Li T, Luo P, Xie Y, Yao XJ, Wang PX, Liu L*. Suppressing mpges-1expression by sinomenine ameliorates inflammation and arthritis [J]. Biochemicalpharmacology, 2017, 142:133-144.

17. Yuan ZW, Li YZ, Liu ZQ, Feng SL, Zhou H, Liu CX, Liu L*, Xie Y*. Role of tangeretin as apotential bioavailability enhancer for silybin: Pharmacokinetic and pharmacologicalstudies [J]. Pharmacological research, 2018, 128:153-166.

18. Wu AG, Zeng W, Wong VK, Zhu YZ, Lo AC, Liu L*, Law BY*. Hederagenin and α-hederinpromote degradation of proteins in neurodegenerative diseases and improve motordeficits in mptp-mice [J]. Pharmacological research, 2017, 115:25-44.

19. Wu JJ, Zhu YF, Guo ZZ, Lou YM, He SG, Guan Y, Zhu LJ, Liu ZQ, Lu LL*, Liu L*. Aconitumalkaloids, the major components of aconitum species, affect expression of multidrugresistance-associated protein 2 and breast cancer resistance protein by activating thenrf2-mediated signalling pathway. Phytomedicine, 2017 Dec 8. doi:10.1016/j.phymed.2017.12.

20. Wang Y, Zhou C, Gao H, Li C, Li D, Liu P, Huang M, Shen X*, Liu L*. Therapeutic effect ofcryptotanshinone on experimental rheumatoid arthritis through downregulating p300mediated-stat3 acetylation [J]. Biochemical pharmacology, 2017, 138:119-129.

21. Wang QQ, Li Y, Xu JH, Wang YW, Leung EL, Liu L*, Yao XJ*. Selective inhibition mechanismof rvx-208 to the second bromodomain of bromo and extraterminal proteins: Insight frommicrosecond molecular dynamics simulations. Scientific reports, 2017, 7 (1):8857.

22. Wang JR, Gao WN, Grimm R, Jiang S, Liang Y, Ye H, Li ZG, Yau LF, Huang H, Liu J, Jiang M,Meng Q, Tong TT, Huang HH, Lee S, Zeng X, Liu L*, Jiang ZH*. A method to identify tracesulfated igg n-glycans as biomarkers for rheumatoid arthritis. Nature communications,2017, 8 (1):631.

23. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ, Leung EL, Liu L*. Honokiol inducesapoptosis, G1 arrest, and autophagy in kras mutant lung cancer cells. Frontiers inpharmacology, 2017, 8:199.

24. Ren X, Chen L, Xie J, Zhang Z, Dong G, Liang J, Liu L, Zhou H, Luo P. Resveratrol amelioratesmitochondrial elongation via drp1/parkin/pink1 signaling in senescent-likecardiomyocytes [J]. Oxidative medicine and cellular longevity, 2017, 2017: 4175353.

25. Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ, Leung EL*, Chow LW*, Liu L*. Shikonin inhibitsgefitinib-resistant non-small cell lung cancer by inhibiting trxr and activating the egfrproteasomal degradation pathway. Pharmacological research, 2017, 115:45-55.

26. Law BY, Mok SW, Chen J, Michelangeli F, Jiang ZH, Han Y, Qu YQ, Qiu CL, Xu SW, Xue WW,Yao XJ, Javed MH, Coghi P, Liu L*. N-desmethyldauricine induces autophagic cell death inapoptosis-defective cells via ca2+ mobilization. Frontiers in pharmacology, 2017, 8:388.

27. Huang L, Dong Y, Wu J, Wang P, Zhou H, Li T, Liu L*. Sinomenine-induced histaminerelease-like anaphylactoid reactions are blocked by tranilast via inhibiting nf-κb signaling.Pharmacological research, 2017, 125:150-160.

28. He F, Wang CJ, Xie Y, Cheng CS, Liu ZQ, Liu L*, Zhou H*. Simultaneous quantification ofnine aconitum alkaloids in aconiti lateralis radix praeparata and related products usinguhplc–qqq–ms/ms. Scientific reports, 2017, 7 (1):13023.

29. Dias IRDSR, Mok SW, Gordillo-Martínez F, Khan I, Hsiao WW, Law BY, Wong VK*, Liu L*.The calcium-induced regulation in the molecular and transcriptional circuitry of humaninflammatory response and autoimmunity. Frontiers in Pharmacology, 2018, 8:962.

30. Wu WJ, Jia WW, Liu XH, Pan LL, Zhang QY, Yang D, Shen XY, Liu L, Zhu YZ. S-propargylcysteineattenuates inflammatory response in rheumatoid arthritis by modulating thenrf2-are signaling pathway. Redox biology, 2016, 10:157-167.

31. Wu J, Lin N, Li F, Zhang G, He S, Zhu Y, Ou R, Li N, Liu S, Feng L, Liu L, Liu Z, Lu L. Inductionof p-glycoprotein expression and activity by aconitum alkaloids: Implication for clinicaldrug–drug interactions. Scientific reports, 2016, 6:25343.

32. Wong VK, Law BY, Yao XJ, Chen X, Xu SW, Liu L*, Leung EL*. Advanced research technologyfor discovery of new effective compounds from chinese herbal medicine and theirmolecular targets. Pharmacological research, 2016, 111:546-555.

33. Su X, Huang Q, Chen J, Wang M, Pan H, Wang R, Zhou H, Zhou Z, Liu J, Yang F, Li T*, Liu L*.Calycosin suppresses expression of pro-inflammatory cytokines via the activation ofp62/nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts.Pharmacological research, 2016, 113:695-704.

34. Liu J, Tang J, Zuo Y, Yu Y, Luo P, Yao X, Dong Y, Wang P, Liu L*, Zhou H*. Stauntoside binhibits macrophage activation by inhibiting nf-κb and erk mapk signalling.Pharmacological research, 2016, 111:303-315.

35. Leung EL, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin VP, Liu L*.Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducingepidermal growth factor receptor degradation via methionine 790 oxidation.Antioxidants & redox signaling, 2016, 24 (5):263-279.

36. Huang Z, Huang Q, Ji L, Wang Y, Qi X, Liu L, Liu Z, Lu L. Epigenetic regulation of activeChinese herbal components for cancer prevention and treatment: A follow-up review [J].Pharmacological research, 2016, 114:1-12.

37. Huang L, Pi J, Wu J, Zhou H, Cai J, Li T*, Liu L*. A rapid and sensitive assay based on particleanalysis for cell degranulation detection in basophils and mast cells [J]. Pharmacologicalresearch, 2016, 111:374-383.

38. Feng S-L, Yuan Z-W, Yao X-J, Ma W-Z, Liu L, Liu Z-Q, Xie Y. Tangeretin, a citruspentamethoxyflavone, antagonizes abcb1-mediated multidrug resistance by inhibiting itstransport function [J]. Pharmacological research, 2016, 110:193-204.

39. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, Lan Z, Chen B, LiY, Zhong H, Xie H, Jie Z, Chen W, Tang S, Xu X, Wang X, Cai X, Liu S, XIa Y, Li J, Qiao X, AIAamaJY, Chen H, Wang L, Wu QJ, Zhang F, Zheng W, Li Y, Zhang M, Luo G, Xue W, Xiao L,Li J, Chen W, Xu X, Yin Y, Yang H, Wang J, Kristiansen K, Liu L, Li T, Huang Q, Li Y, Wang J.The oral and gut microbiomes are perturbed in rheumatoid arthritis and partlynormalized after treatment [J]. Nature medicine, 2015, 21 (8):895.

40. Yuan ZW, Leung EL, Fan XX, Zhou H, Ma WZ, Liu L*, Xie Y*. Quantitative evaluation ofberberine subcellular distribution and cellular accumulation in non-small cell lung cancercells by uplc–ms/ms [J]. Talanta, 2015, 144:20-28.

41. Yang ZF, Leung EL, Liu L, Jiang ZH, Zhong N. Developing influenza treatments usingtraditional chinese medicine [J]. Science, 2015, 347 (6219):S35-S37.

42. Wu AG, Wong VK, Zeng W, Liu L*, Law BY*. Identification of novel autophagic radixpolygalae fraction by cell membrane chromatography and uhplc-(q) tof-ms fordegradation of neurodegenerative disease proteins [J]. Scientific Reports, 2015, 5:17199.

43. Lu LL, Liu XH, Leung EL, Wang Y, Shi J, Hu M, Liu L*, Liu ZQ*. The bioavailability barrier andpersonalized traditional chinese medicine [J]. Science, 2015, 350 (6262):S79-S81.

44. Fan XX, Yao XJ, Xu SW, Wong VK, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, HuangM, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam RK, Liu L*, Leung EL*. (z) 3, 4, 5, 4ʹ-transtetramethoxystilbene,a new analogue of resveratrol, inhibits gefitinb-resistant non-smallcell lung cancer via selectively elevating intracellular calcium level [J]. Scientific reports,2015, 5:16348.

45. Wang JR, Zhang H, Yau LF, Mi JN, Lee S, Lee KC, Hu P, Liu L*, Jiang ZH*. Improvedsphingolipidomic approach based on ultra-high performance liquid chromatography andmultiple mass spectrometries with application to cellular neurotoxicity [J]. Analyticalchemistry, 2014, 86 (12):5688-5696.

46. Leung EL, Wong VK, Jiang ZH, Li T, Liu L*. Integrated network-based medicine: The role oftraditional chinese medicine in developing a new generation of medicine [J]. Science,2014, 346 (6216):S16-S18.

47. Law BY, Chan WK, Xu SW, Wang JR, Bai LP, Liu L*, Wong VK*. Natural small-moleculeenhancers of autophagy induce autophagic cell death in apoptosis-defective cells [J].Scientific reports, 2014, 4:5510.

48. Wong VK, Li T, Law BY, Ma ED, Yip N, Michelangeli F, Law CK, Zhang M, Lam KY, Chan PL,Liu L*. Saikosaponin-d, a novel serca inhibitor, induces autophagic cell death in apoptosisdefectivecells [J]. Cell death & disease, 2013, 4 (7):e720.

49. Leung EL, Cao Z-W, Jiang Z-H, Zhou H, Liu L*. Network-based drug discovery by integratingsystems biology and computational technologies [J]. Briefings in bioinformatics, 2012, 14(4):491-505.

50. Liu L*, Leung EL, Tian X. Perspective: The clinical trial barriers [J]. Nature, 2011, 480(7378):S100-S100.

据2019年12月澳门科技大学官网显示，刘良先后承担或参与了国家自然科学基⾦委员会重点和面上项目、国家科技部重大基础研究项目（973计划和攀登计划）、国家重大新药创制计划、广东省科学基金、香港研究资助局、澳门特区政府科学技术发展基金、香港创新科技署、香港赛马会中药研究院等政府机构资助及企业合作研究项目50多项。

截至2019年11月，刘良以第一发明人获国际专利27项。

自1997年至2009年10月，刘良作为主导师或协助导师培养博士及硕士研究生27名，指导博士后研究人员2名，同时参与研究生及本科生教学，带教学生临床实习。

2009年10月，刘良在安徽医科大学作了题为《中药化学成分药理活性的合理评价与研发复合成分中药新药》的讲座，详细介绍了中药复方的基础研究及其实验室的最新研究结果，充分肯定了中药复方的研究前景。

2013年3月，刘良率领研究团队出席由澳门科技大学主办、澳门科学技术发展基金协办的国家科学技术进步奖成果分享会“中药研究成功之路－从临床到实验室，再回到临床”。

刘良担任世界卫生组织传统医学项目顾问、国际标准化组织（ISO）中医药技术委员会TC249第一工作组主席、世界中医药学会联合会中医药免疫专业委员会会长、澳门风湿病研究国际合作联盟主席、澳门特区政府人才发展委员会委员、科技委员会委员等职务。

刘良是10多种中英文期刊的副主编或编委，包括SCI期刊《Phytomedicine》副主编，及《Pharmacological Research》和《Frontiers of Medicine》等期刊的编委。

2021年3月，受聘担任省部共建中医湿证国家重点实验室、广东省中医药科学院学术委员会副主任。

2022年10月，获聘广药集团首席科学家、广药研究总院名誉院长。

2024年6月23日，当选为广东院士联合会第三届理事会副会长。

刘良曾任国家科技部新药研究与开发专家委员会委员、中华中医药学会理事、中国中西医结合学会中药专业委员会副主任委员、国家中医药管理局及广东省科技项目及成果评审专家、澳门特区政府医务委员会委员、香港卫生署荣誉顾问、香港特区政府中药研究及发展委员会委员、香港赛马会中药研究院董事局董事、香港中医药管理委员会委员及多个中医药专业社团的荣誉顾问等。

刘良当选为中国工程院院士，彰显他在传承创新发展中医药所取得的成就获得国家高度认可，也是澳门科技大学学科建设和高层次人才队伍建设的重大突破，对于提高大学以及澳门的科技创新水平、引领和推动医药卫生事业发展具有重大意义。（澳门科技大学评）

刘良院士在演讲中慷慨传授了数十年的教育管理经验、科研学术成果，贯穿其中的家国情怀、中医情怀以及感恩母校和恩师的情怀，彰显了一个优秀科学家和教育家的博大胸襟。（时任广州医科大学党委书记张建华评）

刘良教授为攻克风湿免疫病、推动中医药现代化和国际化、促进粤港澳三地高等教育合作与发展，以及带领澳门科技大学快速发展做出了卓著贡献。（香港社会企业研究院评）